

³¹**Abstract**

³²**Background:** Primary angle closure glaucoma (PACG) is the leading cause of irreversible blindness 33 in Asia, and no reliable, effective diagnostic, and predictive biomarkers are used in clinical routines. ³⁴A growing body of evidence shows metabolic alterations in patients with glaucoma. we aimed to 35 develop and validate potential metabolite biomarkers to diagnose and predict the visual field 36 progression of PACG.

Methods: Here, we used a 5-phases (discovery phase, validation phase 1, validation phase 2, supplementary phase, and cohort phase) multicenter (EENT hospital, Shanghai Xuhui central 39 hospital), cross-sectional, prospective cohort study design to perform widely-targeted metabolomics 40 and chemiluminescence immunoassay to determine candidate biomarkers. Five machine learning (random forest, support vector machine, lasso, K-Nearest neighbor, and Gaussian NB) approaches were used to identify an optimal algorithm. The discrimination ability was evaluated using the area under the receiver operating characteristic curve (AUC). Calibration was assessed by Hosmer-44 Lemeshow tests and calibration plots.

⁴⁵**Results:** Studied serum samples were collected from 616 participants, and 1464 metabolites were 46 identified. Machine learning algorithm determines that androstenedione exhibited excellent 47 discrimination and acceptable calibration in discriminating PACG across the discovery phase 48 (discovery set 1, areas under the receiver operating characteristic curve $[AUC] = 1.0$ [95%CI, 1.00-⁴⁹1.00]; discovery set, AUC=0.85 [95%CI, 0.80-0.90]) and validation phases (internal validation, ⁵⁰AUC=0.86 [95%CI, 0.81-0.91]; external validation, AUC=0.87 [95%CI, 0.80-0.95]). 51 Androstenedione also exhibited a higher AUC (0.92-0.98) to discriminate the severity of PACG. In 52 the supplemental phase, serum androstenedione levels were consistent with those in aqueous humor 53 (r=0.82, P=0.038) and significantly (P=0.021) decreased after treatment. Further, cohort phase 54 demonstrates that higher baseline androstenedione levels (hazard ratio=2.71 [95% CI: 1.199-6.104], $P=0.017$ were associated with faster visual field progression.

⁵⁶**Conclusion:** Our study identifies serum androstenedione as a potential biomarker for diagnosing 57 PACG and indicating visual field progression.

⁵⁸**Keywords:** primary angle closure glaucoma; metabolomics; androstenedione; diagnose; predict; 59 visual field progression; biomarker

⁶⁰**1. Background**

61 Glaucoma is the most frequent cause of irreversible blindness worldwide¹, and its prevalence is 62 increasing globally, making it a public health concern². The primary form of glaucoma worldwide is 63 Primary Open-Angle Glaucoma (POAG). However, in East Asian populations, Primary Angle-64 Closure Glaucoma (PACG) is predominant, affecting 70% of glaucoma patients globally.^{3–5}. Hence, 65 early detection of PACG and accurate prediction of visual field (VF) changes can potentially 66 preserve vision and mitigate the risk of PACG advancement. Measurement of intraocular pressure, 67 perimetry, gonioscopy and optical coherence tomography is the main diagnostic testing to assess for 68 glaucoma and to monitor for disease progression⁶. However, the present clinical techniques are ⁶⁹inadequate for the early diagnosis and prognosis of VF progression as they depend on specialized ⁷⁰eye examination equipment and the expertise of ophthalmologists. Furthermore, patients seldom seek 71 the services of an ophthalmologist until the symptoms worsen or visual acuity significantly 72 deteriorates. Importantly, the He et al.⁷ study taught us that performing laser iridotomy on patients 73 with 180 degrees of angle closure does not prevent PACG, thus gonioscopy may not a good tool to ⁷⁴help distinguish PACG from controls. Therefore, the development of a straightforward and ⁷⁵dependable biomarker or biomarker panel to facilitate early detection and prognostication of 76 progressive visual field loss in primary angle-closure glaucoma is imperative, rather than relying 77 solely on the expertise of ophthalmologists and specialized equipment.

⁷⁸Multiple etiology and risk factors lead to the onset/development of PACG in humans, which involves 79 a tremendous flow of physiological changes, genetic factors, and metabolic adaptations⁸. Both 80 physiological changes, genetic factors, and metabolic adaptations should lead to profound changes in 81 most metabolic pathways. Small molecule metabolites, as crucial biomarkers of cellular function⁹, 82 which identifies and quantified by metabolomics, are the omics product closest to clinical 83 phenotypes¹⁰. A burgeoning corpus of evidence indicates metabolic changes in individuals afflicted 84 with glaucoma^{11–15}. Nevertheless, extant metabolomics research on glaucoma is constrained by ⁸⁵inadequate sample sizes, a dearth of validation sets to corroborate findings, and an absence of 86 specificity analyses. Notably, investigations have yet to comprehensively characterize the serum 87 metabolome in sizable cohorts to identify putative biomarkers capable of distinguishing patients with 88 PACG from healthy controls.

89 In this study, a cross-sectional and prospective cohort design was employed to systematically profile ⁹⁰blood metabolites using widely-targeted metabolomics and chemiluminescence immunoassay in both 91 patients with primary angle-closure glaucoma (PACG) and control individuals. The objectives of the 92 study were to characterize the metabolic profile associated with PACG, identify potential blood 93 diagnostic biomarkers of PACG, assess the specificity of diagnostic biomarkers for PACG of any 94 severity, and verify the biomarkers used to predict the visual field progression of PACG.

95

⁹⁶**2. Methods**

⁹⁷**2.1 Participant**

⁹⁸From January 2020 to December 2021, newly diagnosed PACG and age-sex-matched controls were 99 recruited from the Eye Center of Fudan University and Shanghai Xuhui Central hospital. Detailed 100 ophthalmic examinations and medical examinations were described in the supplementary material. ¹⁰¹Approval from the Institutional Review Board/Ethics Committee (2020[2020013]) was obtained 102 from the Ethics Committee of the Eye and ENT Hospital, and the study adhered to the principles of 103 the Declaration of Helsinki. Informed consent was obtained from all subjects.

¹⁰⁴A glaucoma specialist diagnosed PACG. The diagnostic criteria for PACG were described 105 previously^{16–18} and detailed in the supplementary material. The inclusion and exclusion criteria of 106 patients with PACG were described previously^{16–18} and detailed in the supplementary material. The 107 methods performed for VF analysis were done as previously described^{16,18} and detailed in the 108 supplementary material. Previously described methods^{16,18–20} were performed for the determination 109 of functional PACG VF loss progression according to an event-based analysis modified for Octopus 110 perimetry.

¹¹¹**2.2 Study design**

¹¹²A cross-sectional, multicenter, prospective cohort study design. In the cross-sectional study, a total of ¹¹³616 patients and controls were prospectively enrolled from the Eye Center of Fudan University and ¹¹⁴Shanghai Xuhui Central hospital which was divided into 4 phases (discovery phase [discovery set 1, 115 the discovery set 2], validation phase 1 [external validation], validation phase 2 [internal validation], 116 supplemental phase) from eight districts in China (Figure S1). The 5 phases of the study are 117 independent and are shown in Figure 1. The discovery set 1 was composed of 80 serum samples

118 from PACG patients and 60 samples from controls which was enrolled from Eye Center of Fudan 119 University between January 2020 to June 2020. The discovery set 2 was composed of 100 serum 120 samples from PACG patients and 80 samples from controls which was enrolled from Eye Center of 121 Fudan University between July 2020 to Deccember 2020. The differential metabolites of discovery 122 set 1 and discovery set 2 were obtained by widely-targeted metabolomics. The intersection of the 123 differential metabolites of the two discovery sets was used as a candidate biomarker. For validation 124 phase 1, serum samples from 70 PACG patients and 50 controls were collected which was enrolled 125 from Shanghai Xuhui Central hospital between January 2020 to December 2020. Candidate 126 biomarkers were validated in validation phase 1 using widely-targeted metabolomics, and potential 127 biomarkers were obtained. For validation phase 2, serum samples from 98 PACG patients and 78 128 controls were collected which was enrolled from Eye Center of Fudan University between January ¹²⁹2021 to December 2021. Potential biomarkers were validated in validation phase 2 using 130 chemiluminescence methods. For the supplemental phase, we used widely-targeted metabolomics to ¹³¹investigate whether the same potential biomarkers were present in PACG patients' aqueous humor. ¹³²All the clinical characteristics (Age, sex, BMI, hypercholesterolemia, hypertension, diabetes, ¹³³smoking, drinking) were matched between PACG and controls in the 4 phases.

¹³⁴In the prospective cohort study, 98 newly diagnosed PACG patients were included from the Eye 135 Center of Fudan University between January 2020 and December 2020. All participants visited once 136 every six months to allow regular assessment of PACG disease progression (the minimum follow-up 137 period was set to 24 months). Serum samples from 98 PACG patients were collected and measured 138 using chemiluminescence methods. Detailed information of patients follow up were described as 139 previously $16,18$.

¹⁴⁰**2.3 Sample preparation**

¹⁴¹**2.3.1 Sample collection**

¹⁴²The blood was collected prior to the medical or surgical treatment. Briefly, subjects were asked to 143 ensure about eight-ten hours of fasting before sampling. Venous blood samples were collected in ¹⁴⁴heparinized tubes between 7:00-9:30 am. The clinical laboratory obtained the sample at about 10:00 145 am and centrifuged them at 3000rpm for 10min. Then serum was collected into a sterilized cryotube 146 and immediately stored at -80 for metabolomic analysis.

147 The acquisition of aqueous humor was described previously¹³. Aqueous humor (AH) was collected ¹⁴⁸by skilled ophthalmologists during the surgical treatment of PACG and cataract patients. AH was 149 obtained at the start of the procedure using a fine-bore needle during a corneal paracentesis. 150 Following that, AH samples were quickly transferred to sterile cryotubes and kept at -80 \degree C for 151 metabolomic analysis.

¹⁵²**2.3.2 Sample preprocessing**

¹⁵³The same internal standard was added to each sample during metabolite extraction (L-2- 154 chlorophenylalanine, 4-Fluoro-L-α-phenylglycine, [2H5]-Kynurenic Acid, [2H5]-Phenoxy acetic ¹⁵⁵Acid, Indole-3-butyric-2,2-d2 Acid, LysoPC 19:0, DL-3-Indole-lacticacid). Before extraction, the 156 serum was thawed on ice, vortex for 10s and mixed well. 300µL of pure cold methanol was added to 157 50 μ L of serum, swirled for 3min, and centrifuged at 12000 rpm for 10min at 4 \degree C. After 158 centrifugation, transfer the supernatant into a new centrifuge tube and place it in a -20 refrigerator 159 for 30 minutes. The sample was thawed on ice and centrifuged at 12000r/min for 3 minutes— 160 Transfer 180μ L of the supernatant to the injection vial for mass spectrometry analysis. Quality 161 control (QC) samples are generated by pooling all the serum samples to monitor the retention time 162 and signal intensity consistency. Equal volumes (10 μ L) of all serum samples were combined to 163 generate quality control (QC) samples, which were employed to monitor the repeatability of the 164 analysis. During the mass spectrometry analysis, one QC sample was included in every ten samples 165 to ensure the consistency of the analytical process(sheet1). The PACG and control groups' serum 166 samples were randomly arranged and analyzed. The laboratory conducting the metabolomics 167 measurements was blinded to the samples' case/control/QC status.

2.4 Analytical methods ²¹ ¹⁶⁸

¹⁶⁹**2.4.1 Untargeted metabolomics analysis**

170 Ultra Performance Liquid Chromatography (UPLC) (ExionLC AD, AB SCIEX) separation was 171 performed using Waters ACQUITY HSS T3 $(2.1\times100$ mm, 1.8um). The oven temperature was set to 172 $40\degree$, and the sample injection volume was 5 µL. Metabolites were eluted from the column at a flow 173 rate of 0.35 mL/min. Mobile phases for UPLC consisted of 0.1% acetic acid in water (phase A) and ¹⁷⁴0.1% acetic acid in acetonitrile (phase B). The following gradient elution program was employed: 0- 175 10min: linear gradient from 5% to 90% B; 10-11min: 90% B; 11-11.1min: linear gradient from 90%

176 to 5% B; 11.1-14min: 5% B. Metabolic extracts mixture (QC sample) were analyzed by the triple 177 time of flight (TOF) mass spectrometer (TripleTOF 6600, AB SCIEX) in both positive and negative 178 ionization modes. The scan range was 50-1,000 m/z. Electrospray ionization (ESI) source conditions 179 were set as follows: ion spray voltage (IS) 5500V (positive), -4500V (negative); ion source gas I ¹⁸⁰(GSI), gas II (GASII), curtain gas (CUR) was set at 50,50, and 25 psi, respectively; collision energy 181 (CE) 30V.

¹⁸²**2.4.2 Widely targeted detection conditions**

¹⁸³UPLC (ExionLC AD, AB SCIEX) separation was performed using Waters ACQUITY UPLC 184 C18(2.1×100mm, 1.8um). The oven temperature was set to $40\degree$, and the sample injection volume 185 was 2 µL. Metabolites were eluted from the column at a flow rate of 0.35 mL/min. Mobile phases for ¹⁸⁶UPLC consisted of 0.1% acetic acid in water (phase A) and 0.1% acetic acid in acetonitrile (phase B). 187 The following gradient elution program was employed: 0-11min: linear gradient from 5% to 90% B; ¹⁸⁸11-12min: 90% B; 12-12.1min: linear gradient from 90% to 5% B; 12.1-14min: 5% B. Metabolic 189 extracts of each sample were analyzed by the triple quadrupole-linear ion trap mass spectrometer ¹⁹⁰(QTRAP 6500, AB SCIEX) in both positive and negative ionization modes. ESI source conditions 191 were set as follows: ion spray voltage (IS) 5500V (positive), -4500V (negative); ion source gas I ¹⁹²(GSI), gas II (GASII), curtain gas (CUR) was set at 50,50, and 25 psi, respectively. Each ion pair is 193 scanned for detection based on optimized voltage and CE.

¹⁹⁴**2.4.3 Metabolite profiling**

195 Mixed samples (QC sample) were made and tested by AB Triple TOF 6600 mass spectrometer, the ¹⁹⁶metabolites identified base on public database including Metware public database (Metlin, HMDB, 197 KEGG), and MetDNA. The detected metabolites of QC sample (metabolites with a total score > 0.5) 198 add Metware in-house database to be a new whole database. MRM was used for each samples to 199 determine the final ion pair and other information. Based on the new database, Q-trap 6500 was used 200 to quantify all samples accurately. The workflow of mass spectrometry is detailed in Figure S2.

²⁰¹**2.4.4 Data processing**

²⁰²All LC-MS data were processed using Analyst 1.6.3 for imputing raw, peak picking, alignment, 203 normalization, and to produce peak intensities for retention time and m/z data pages. The features were 204 selected based on their CV with QC samples. Features with CVs of more than 15% were eliminated.

²⁰⁵**2.4.5 Chemiluminescence immunoassay**

²⁰⁶Serum levels of androstenedione were measured using a commercially available kit (Snibe ²⁰⁷Diagnostics, Shenzhen, China) and were determined using the chemiluminescent immunoassay 208 method by Roche Cobase e 601 (Germany).

²⁰⁹**2.5 Sample size and missing value**

210 In the cross-sectional study, to calculate the minimum total sample size, we used an open-source 211 calculator based on the methods described by Obuchowski et al.²² and Li et al.²³. The input

212 parameters were specificity = 0.9 (allowable error = 0.05), sensitivity = 0.9 (allowable error = 0.05),

213 $\alpha = 0.05$ (2-tailed). Based on this calculation, the minimum sample size required for the new

214 biomarker was 98 per phase.

²¹⁵An unreliable conclusion would result from missing data, which would introduce bias. Thus no 216 patients with missing data were included in this study. In this study, a total of 48 participants (lack of

217 VF value = 18, lack of medication history record = 12, lack of intraocular pressure [IOP] value = 10,

218 loss to follow-up = 8) were excluded due to with missing data.

²¹⁹**2.6 Statistical analysis**

220 Normality was assessed using the Shapiro–Wilk W-test. Independent student's t-test, Kruskal-Wallis 221 test, one-way ANOVA, Wilcox test, and chi-square tests were used when appropriate. Results are 222 presented as frequency and percentage for categorical variables, mean \pm SD for normally distributed 223 continuous variables, and median (interquartile range) for not normally distributed continuous 224 variables. The Spearman correlation test was used to determine the significance of the correlations 225 between the variables.

226 Diagnostic efficiency was evaluated using receiver operating characteristic (ROC) curves. Five 227 machine learning (random forest, support vector machine, lasso, K-nearest neighbor [KNN], and 228 Gaussian Naive Bayes [NB]) approaches were used to identify an optimal algorithm. The Youden 229 index maximizing sensitivity plus specificity is applied to determine the best cutoff value, sensitivity, 230 specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) were also 231 calculated. Hosmer-Lemeshow tests were used to assess the goodness of fit. The calibration of the ²³²biomarker was assessed by computing the calibration plot. Hanley-McNeil method was used to 233 compare these AUCs.

²³⁴Unsupervised principal component analysis (PCA) was performed by statistics function prcomp 235 withe R. The data was unit variance scaled before unsupervised PCA. Supervised orthogonal 236 projections to latent structures-discriminate analysis (OPLS-DA) were applied to obtain a higher ²³⁷level of group separation and a better understanding of variables responsible for classification. 238 Heatmaps of samples and metabolites were carried out by R package (ComplexHeatmap; heatmap). ²³⁹In order to evaluate the binding mode of metabolites and proteins, Autodock Vina v.1.2.2 was used to 240 analyze molecular docking. Fold change= the characteristic peak area of metabolites in the PACG 241 group / the control group.

242 Identified metabolites were annotated using the KEGG Compound database ²⁴³(http://www.kegg.jp/kegg/ compound/). Then annotated metabolites were mapped to the KEGG 244 Pathway database (http://www.kegg.jp/kegg/pathway.html). Significantly enriched pathways were 245 identified with a hypergeometric test's p-value for metabolites.

- ²⁴⁶Cox proportional hazards analysis was also carried out to investigate the relationship between 247 baseline androstenedione levels and VF progression loss. The HRs and baseline characteristics that 248 would assist in categorizing participants into the non-progressing PACG group over the follow-up 249 period were determined using Cox proportional hazards models. Kaplan-Meier plots were used to 250 study the survival results, and the log-rank test was applied to see whether there were any differences 251 between the produced plots.
- ²⁵²All statistical analyses were performed using R programming language and SPSS 13.0 (SPSS Inc.,
- 253 Chicago, IL, USA), a list of statistical approaches and packages detailed in table S1. P-values less
- 254 than 5% were considered statistically significant.

²⁵⁵**Role of funding sources**

256 The funder of the study had no role in study design, data collection, data analysis, data interpretation, 257 or writing of the report.

²⁵⁹**3. Results**

²⁶⁰**3.1 Metabolomic analyses in samples from PACG patients and normal controls**

- 261 The design of this study is depicted in Figure 1, while the clinical features of all participants in the
- 262 four phases of the study are presented in Tables 1 (Phases 1-3) and S2-S3 (Phase 4). All clinical

263 characteristics, including age, sex, BMI, hypercholesterolemia, hypertension, diabetes, smoking, and 264 drinking, were carefully matched between the PACG and normal control groups across all four 265 phases.

²⁶⁶Following rigorous quality control, data filtering, and normalization procedures, a total of 1464 267 metabolites were identified across the various samples ($N = 440$). During the discovery phase, the ²⁶⁸OPLS-DA analysis revealed notable distinctions between participants with primary angle-closure 269 glaucoma (PACG) and those without the condition (Figure 2A). Volcano plots (Figure 2B) were 270 generated using metabolites exhibiting a false discovery rate [FDR] of less than 0.1 and fold changes 271 greater than 1.15 or less than 0.85. In discovery sets 1 and 2, 268 metabolites (21.5%) and 117 ²⁷²metabolites (9.6%), respectively, were found to be significantly altered between PACG and normal 273 subjects.

²⁷⁴The Venn diagram depicted in Figure 2C illustrates the presence of 32 metabolites that were found to 275 be common in both discovery set 1 (as presented in table S4) and discovery set 2 (as presented in 276 table S5). The parameters used for detecting these 32 differential metabolites are detailed in Table S6. 277 Subsequently, these differential metabolites were utilized for conducting clustering analysis, which is 278 visually represented in the form of a heatmap for both discovery set 1 (Figure 2D) and discovery set 279 2 (Figure 2E). These 32 differential metabolites were mainly related to alcohol and amines, amino 280 acid and its metabolomics, benzene and substituted derivatives, fatty acid, heterocyclic compounds, 281 hormones, and hormone-related compounds, nucleotide and its metabolomics, organic acid and its 282 derivatives class (Figure 2D, 2E).

²⁸³**3.2 The blood differential metabolite discriminates PACG from normal**

²⁸⁴Can these metabolites in blood differentials be considered as potential biomarkers for PACG? In 285 order to investigate this, we computed the area under the curve (AUC) for each of the 32 differential 286 metabolites to evaluate their discriminatory capacity in distinguishing PACG from healthy 287 individuals using five machine learning techniques (random forest, support vector machine, lasso, 288 KNN, and Gaussian NB). Among these approaches, KNN demonstrated the highest performance in 289 identifying PACG from normal controls. Subsequently, a 2-column heatmap was generated to display 290 the resulting area under the curve (AUC) values for discovery set 1 and discovery set 2, respectively, 291 as depicted in Figure 3A. The receiver operating characteristic (ROC) analysis of 32 metabolites

292 revealed AUC values ranging from 0.74 to 1.0 in discovery set 1 and 0.72 to 1.0 in discovery set 2 293 for distinguishing PACG from normal subjects. The eigenmetabolite of the 32-metabolite cluster 294 between PACG and normal subjects is illustrated in Figure 4B and 4C. The discriminatory accuracy 295 of the metabolite in differentiating PACG from normal subjects using random forest, support vector 296 machine, lasso, and Gaussian NB is presented in Figure S3.

297 The present study reveals that the eigenmetabolite levels were markedly elevated $(P<0.001)$ in the 298 normal group compared to the PACG group, as evidenced by the results obtained from discovery set 299 1 (Figure 3B) and discovery set 2 (Figure 3C). These findings provide compelling evidence that the

300 heightened risk of PACG is linked to a robust blood metabolite signature.

³⁰¹**3.3 Biomarker discovery to discriminates PACG from normal**

302 Figure 3A illustrates that 32 metabolites were verified during the discovery phase and were 303 subsequently identified as potential biomarkers. Figure 4A depicts a correlation analysis between 304 ocular clinical characteristics and the 32 potential biomarkers discovered during the PACG discovery 305 phase. Notably, a significant positive correlation was observed between androstenedione and the 306 mean deviation of the VF (MD) ($r=0.45$, P<0.001). This correlation was also observed in discovery 307 set 1 (Figure S3, r=0.37, P<0.001) and discovery set 2 (Figure S4, r=0.50, P<0.001), respectively. A 308 statistically insignificant (P>0.05) correlation was observed between ocular clinical characteristics 309 and the remaining 31 potential biomarkers, as depicted in Figure 3A, Figure S3, and Figure S4. 310 Notably, the level of androstenedione was found to be significantly higher in PACG patients than in 311 normal subjects in both discovery set 1 (Figure 4B, P=0.0081, Normal:33987 \pm 11113, PACG:42852 312 \pm 20767) and discovery set 2 (Figure 4C, P=0.0078, Normal:31559 \pm 10975, PACG:37934 \pm 18529). 313 Additionally, high levels of androstenedione were identified as an independent risk factor for PACG, 314 as shown in Table S7. Figure S5 (Discovery set 1) and Figure S6 (Discovery set 2) illustrate the 315 levels of the remaining 31 metabolites between PACG patients and normal subjects. Based on the 316 preceding analysis, androstenedione was chosen using KNN due to its ability to differentiate between 317 PACG and normal subjects. In discovery set 1, the AUC for PACG versus control was 1.0 (95% CI, 318 1.0 to 1.0), as shown in Figure 4D and Table S8. Similarly, in discovery set 2, PACG was identified 319 with an AUC of 0.85 (95% CI, 0.80 to 0.90) when compared to control individuals, as depicted in 320 Figure 4E and Table S8.

³²¹**3.4 Biomarker validation in two independent validation phases**

³²²During the validation phases, Androstenedione was evaluated as a biomarker signature. The samples 323 from validation phase 1 were subjected to LC-MS analysis for widely-targeted metabolomics, which 324 revealed significant differences between PACG and normal participants, as demonstrated by the 325 OPLS-DA analysis (Figure S7). In validation phase 2, a chemiluminescence immunoassay method 326 was developed to enable precise quantification of serum androstenedione levels in a convenient and 327 rapid manner.

³²⁸During validation phase 1 and 2, the level of androstenedione was found to be significantly higher in

329 individuals with PACG compared to normal subjects (Figure 5A, P=0.0042, Normal:60737 \pm 28078,

330 PACG:82394 \pm 33994; Figure 5B, P=0.0034, Normal:1.552 \pm 0.489, PACG:1.825 \pm 0.6876). The

331 performance of androstenedione was evaluated using the AUC in ROC analysis. The AUC for PACG

332 versus control was 0.87 (95% CI, 0.80 to 0.95) in validation phase 1, as depicted in Figure 5C and

³³³Table S8. In validation phase 2, a consistent performance of androstenedione (AUC, 0.86, 95% CI,

334 0.81 to 0.91) was observed (Figure 5D, Table S8).

³³⁵**3.5 Biomarker validation in male and female subgroups**

336 Validation of androstenedione as a biomarker for PACG necessitates consideration of sex, as males 337 exhibit 5-10 times higher levels of this hormone than females. Accordingly, the subjects were 338 stratified into male and female subgroups.

- ³³⁹Figure S8 demonstrates that in the discovery phase, the AUC for PACG compared to control was 1.0
- ³⁴⁰(95% CI, 1.0 to 1.0) in the male subgroup (Figure S8A), and 0.91 (95% CI, 0.85 to 0.98) in the
- 341 female subgroup (Figure S8B). In validation phase 1, the AUC for PACG versus control was 0.83 (95%)
- ³⁴²CI, 0.73 to 0.92) in the male subgroup (Figure S8C), and 1.0 (95% CI, 1.0 to 1.0) in the female
- 343 subgroup (Figure S8D). In validation phase 2, the AUC for PACG versus control was 1.0 (95% CI,
- ³⁴⁴1.0 to 1.0) in the male subgroup (Figure S8E), and 0.88 (95% CI, 0.79 to 0.98) in the female
- 345 subgroup (Figure S8F).

³⁴⁶**3.6 Androstenedione associates with severity of PACG**

347 The present study aimed to examine the potential association between serum androstenedione levels

- 348 and the clinical severity of PACG. PACG severity was categorized into mild (MD \leq 6), moderate (6-
- 349 12), and severe (MD >12) based on the MD value. The results from both discovery set 1 (Figure S9A,

350 Mild:32600 \pm 17011, Moderate:33215 \pm 17855, Severe:46060 \pm 21789) and discovery set 2 (Figure 351 S9B, Mild:27866 \pm 19873, Moderate:27057 \pm 13166, Severe:43972 \pm 19234) indicated that the mean 352 serum androstenedione levels were significantly higher in the severe PACG group compared to the 353 moderate and mild PACG groups (P<0.001). These findings were further validated in both validation 354 phase 1 (Figure S9C, Mild:75726 \pm 45719, Moderate:65798 \pm 30610, Severe:94348 \pm 30858) and 355 validation phase 2 (Figure S9D, Mild:1.121 \pm 0.3143 ng/ml, Moderate:1.461 \pm 0.4391 ng/ml, 356 Severe: 2.147 ± 0.6476 ng/ml).

³⁵⁷A correlation analysis was conducted to examine the relationship between MD and androstenedione. 358 Notably, a statistically significant positive correlation was found between MD and androstenedione 359 in both discovery set 1 (Figure S3, r=0.37, P<0.001) and discovery set 2 (Figure S4, r=0.50, 360 P<0.001). This finding was further confirmed in validation phase 2 (Figure S9E, r=0.61, P<0.001). 361 Subsequently, the diagnostic potential of androstenedione in distinguishing the severity of PACG was 362 investigated. An AUC was calculated for each severity of PACG to evaluate the discriminatory 363 accuracy of androstenedione in distinguishing between mild, moderate, and severe cases. The results 364 of ROC analysis indicated AUC values ranging from 0.75 to 0.95 in discovery set 1 (Figure S10A, 365 Table S8) and 0.94 to 0.99 in discovery set 2 (Figure S10B, Table S8) when using KNN machine 366 learning algorithms. The validity of androstenedione in distinguishing the severity of PACG was 367 demonstrated through consistent performance in both validation phase 1 (Figure S10C, Table S8, ³⁶⁸AUC of 0.64-0.97) and validation phase 2 (Figure S10D, Table S8, AUC of 0.98-1.0). Additionally, 369 when mild and moderate cases were combined, the AUC for mild and moderate versus severe was ³⁷⁰0.94 (95% CI 0.89 to 0.99) in discovery set 1 (Figure S9F, Table S8), 0.93 (95% CI 0.88 to 0.98) in 371 discovery set 2 (Figure S9G, Table S8), 0.92 (95% CI 0.85 to 0.99) in validation phase 1 (Figure S9H, 372 Table S8), and 0.98 (95% CI 0.96 to 1.0) in validation phase 2 (Figure S9I, Table S8).

³⁷³**3.7 Clinical value of androstenedione in patients with PACG**

374 The lack of specificity of serum biomarkers remains a significant obstacle to the clinical application 375 of such markers. To investigate temporal changes in androstenedione levels during the initial 376 diagnosis and post-treatment period, we conducted a random analysis of nine pairs of blood samples 377 from patients taken before and three months after surgical treatment (Figure 6A). Our findings 378 indicate a significant decrease in androstenedione levels in the post-treatment serum of the nine

379 patients compared to the pre-treatment serum ($P = 0.021$, Figure 6B).

380 A case-control study (PACG=7, Cataract=11) (Figure 6C) was conducted to investigate the potential 381 elevation of aqueous humor levels of androstenedione in patients. The findings revealed a 382 statistically significant increase $(P=0.011)$ in the levels of androstenedione in the aqueous humor of 383 patients with PACG compared to those with cataracts (Figure 6D). Additionally, a significantly 384 positive correlation between MD and aqueous humor levels of androstenedione was observed (Figure ³⁸⁵6E, r=0.98, P<0.001). The mean aqueous humor levels of androstenedione were found to be 386 significantly higher (P<0.001) in the severe PACG group compared to the moderate and mild PACG 387 groups (Figure 6F). Subsequently, an examination was conducted on seven paired serum-aqueous ³⁸⁸humor samples obtained from identical PACG patients to ascertain the presence of a consistent 389 pattern within the same individuals. A statistically significant correlation was observed between the 390 levels of androstenedione in serum and aqueous humor ($r=0.82$, P=0.038) (Figure 6G).

³⁹¹**3.8 Calibration ability of androstenedione on discovery phase and validation phase**

³⁹²Figure S11 displays the calibration plots for both the discovery and validation phases, which ³⁹³effectively validate the calibration performance of serum androstenedione for probability. The plots ³⁹⁴demonstrate a high level of agreement between predicted and observed values in both discovery set 1 ³⁹⁵(Figure S11A) and discovery set 2 (Figure S11B). The Hosmer-Lemeshow test yielded a 396 nonsignificant statistic in the discovery set 1 (χ^2 =0, P=1) and discovery set 2 (χ^2 =6.16, P=0.10), indicating no departure from a perfect fit. Validation phase 1 (Figure S11C, χ^2 =5.14, P=0.14) and 398 validation phase 2 (Figure S11D, χ^2 =1.25, P=0.26) resulted in similar performance.

³⁹⁹**3.9 Androstenedione could predict VF progression in patients with PACG**

⁴⁰⁰This study comprised 97 participants diagnosed with PACG, selected based on the screening criteria 401 and followed up for a period of 24 months. In cases of bilateral PACG, one eye was selected at 402 random. Of the total participants, 44 (45.36%) exhibited glaucoma progression, as evidenced by 403 visual field (VF) loss. The demographic and ocular features of the VF progressing and non-404 progressing groups at baseline are presented in Table S9.

405 The patients in the progression group exhibited a statistically significant increase $(P<0.001)$ in the ⁴⁰⁶mean serum levels of androstenedione compared to those in the non-progressing group (refer to 407 Table S9). Furthermore, the multivariate Cox analysis revealed that the baseline levels of

408 androstenedione (HR=2.71, 95% CI=1.20–6.10, P=0.017) were significantly associated with 409 glaucoma progression, as determined by the VF loss results (Table 2). Figure 7 displays the Kaplan-⁴¹⁰Meier survival curves. The results of the survival analysis revealed a statistically significant increase 411 in the proportion of patients with elevated androstenedione levels who experienced VF progression 412 in PACG (log-rank test, P<0.001, Figure 7A). Comparable findings were observed in both the female 413 (log-rank test, P=0.0042, Figure 7B) and male (log-rank test, P=0.0014, Figure 7C) subgroups.
414

⁴¹⁵**4. Discussion**

416 The delayed identification of PACG is a notable contributor to patients' impaired vision and 417 irreversible blindness. Regrettably, existing medical protocols do not advocate for the use of blood-418 based biomarkers to diagnose and prognosticate PACG. Consequently, it is imperative to develop 419 novel, uncomplicated, and practicable approaches to improve the early detection of PACG and its 420 predictive accuracy. To address the significant challenge at hand, the present study conducted a 421 cross-sectional and prospective cohort investigation utilizing high-throughput, widely-targeted ⁴²²metabolomics and targeted chemiluminescence immunoassay on blood samples obtained from a ⁴²³substantial number of patients diagnosed with PACG and healthy individuals. The findings of this 424 study reveal, for the first time, that androstenedione exhibits a reasonable level of precision (AUC, 425 0.85-1.0) in distinguishing between PACG and control groups in blood samples. Additionally, the 426 baseline levels of androstenedione may serve as a valuable predictor of glaucomatous visual field 427 progression.

428 Some metabolites have been proposed to have a potential role in discriminating PACG from normal, 429 but validation studies in larger cohorts still need to be completed. Rong et al. 14 conducted a case-430 control (PACG=38, normal=48) study using gas chromatography-mass spectrometry and reported 431 that palmitoleic acid, linoleic acid, γ-linolenic acid, and arachidonic acid were identified as essential 432 metabolites associated with PACG, but diagnostic accuracy is unknown. In our study, these 433 metabolites were also detected, but diagnosis accuracy (AUC<0.7) was limited. Qin et al.²⁴ measured ⁴³⁴plasma twenty-two free fatty acids (FFA) and six lipid classes using metabolomics analysis, shown 435 that docosahexaenoic acid (DHA) and total saturated fatty acids may be screening indices (AUC, 436 0.82-0.85) for PACG patients but lack validation set to confirm the results. DHA (AUC, 0.74-0.85),

⁴³⁷FFA (22:6) (AUC, 0.74-0.85), and FFA (18:4) (AUC, 0.79-1.0) was also shown a diagnose value for ⁴³⁸PACG patients in the discovery set of our study (Figure 3A), but the robustness and diagnose 439 accuracy was weaker than androstenedione (AUC, 0.85-1.0) (Table S10). The contribution of ⁴⁴⁰previous metabolites to PACG diagnosis was small, which prompted us to conduct a trial designed to 441 develop biomarkers.

⁴⁴²In this study, androstenedione levels achieved better diagnostic efficiency and robust calibration ⁴⁴³across the discovery and validation sets. The transformation of normal subjects into PACG is a ⁴⁴⁴chronic stepwise process. Given this, screening healthy individuals and those with a family history of 445 the disease is vital. Another important finding of this research was that the level of serum 446 androstenedione retained its diagnostic efficiency for distinguishing the severity of PACG. ⁴⁴⁷Furthermore, serum androstenedione levels incrementally increased from mild to moderate to severe ⁴⁴⁸PACG, suggesting that serum androstenedione levels may accurately reflect the progression/severity 449 of PACG. Furthermore, androstenedione levels at baseline were a new biomarker for predicting ⁴⁵⁰glaucomatous VF progression. Hence, serum androstenedione levels may provide a new biomarker 451 for early detection and monitoring/predicting PACG severity/progression.

⁴⁵²In the supplemental phase, we asked whether the serum levels of androstenedione were significantly 453 correlated with aqueous humor levels of androstenedione from the same PACG patients, which is an ⁴⁵⁴important criterion for application as a routine clinical biomarker and to explore the biological 455 function in PACG. Fortunately, the levels of aqueous humor androstenedione were positively 456 correlated $(r=0.82, P=0.038)$ with serum levels. Meanwhile, the levels of aqueous humor ⁴⁵⁷androstenedione incrementally increased from mild-moderate to severe PACG. Furthermore, the ⁴⁵⁸levels of aqueous humor androstenedione remained higher in PACG than in cataracts. Together, these 459 results confirm that androstenedione can serve as a novel biomarker for early detection and 460 monitoring of the progression/severity of PACG.

⁴⁶¹In clinical practice, oral topical glaucoma medications and laser peripheral iridectomy were the 462 primary therapies used to treat PACG. However, the effects of these therapies are mainly estimated ⁴⁶³by measurement of intraocular pressure and optical coherence tomography. Thus, we have wondered ⁴⁶⁴whether, by dynamic detection, serum androstenedione levels could reflect the therapeutic effect of 465 these therapies. In the supplemental phase (fourth phase), in a small cohort of 9 PACG patients

466 treated with laser peripheral iridectomy or oral topical glaucoma medications, which showed a better 467 prognosis, 7 of 9 exhibited decreased levels of serum androstenedione. These results shed new light 468 on the monitor the effect of therapy; however, these should be verified in a larger cohort.

⁴⁶⁹The main strength of our study is its robustness. We conducted a 5-phase study (discovery set 470 [discovery set 1, the discovery set 2], validation phase 1, validation phase 2, supplemental phase, and 471 cohort phase). We used large and well-characterized patients with adequate controls to confirm the 472 results. Widely-targeted metabolomics and target chemiluminescence immunoassay methods provide 473 high reliability of the metabolite. Androstenedione achieved better diagnostic accuracy across the 474 discovery and validation sets, with AUC varying between 0.85 and 1.0. Interestingly, baseline ⁴⁷⁵androstenedione levels can predict glaucoma progression via VF loss results. Of note, the clinical 476 practice of androstenedione in patients with PACG was analyzed by supplemental phase.

477 The metabolites identified by this study match PACG pathophysiological concepts. Pathway 478 enrichment analysis demonstrated that these 32 significantly altered metabolites primarily belonged 479 to 16 pathways (Figure S12). Among the top altered pathways, steroid hormone biosynthesis appears 480 to be the critical node to high-match PACG pathophysiological concepts^{25,26}: it connects with ⁴⁸¹androstenedione. The molecular formula of androstenedione is shown in Figure S13. Steroid 482 hormone biosynthesis appears to be a key node in the pathophysiological concept of highly matched ⁴⁸³PACG, but high enrichment is observed in metabolic pathways. Hormones play critical roles in ⁴⁸⁴various physiological functions, such as metabolism, immune responses, and inflammation ⁴⁸⁵regulation. In a related study on fatigue experienced during Androgen Deprivation Therapy (ADT), ⁴⁸⁶marked disparities were found in metabolite levels in the steroid hormone biosynthesis pathways, ⁴⁸⁷underscoring their significance in metabolic shifts. These insights highlight the intricate 488 interconnection between steroid hormone biosynthesis and other metabolic pathways^{27,28}. The sex 489 hormones pathway is a vital component of steroid hormone biosynthesis (Figure S14A). Several 490 studies have focused on the importance of 17β-estradiol in protecting the retinal ganglion cell layer 491 and preserving visual function in clinical²⁹ and basic²⁵ research by anti-inflammatory effect³⁰. Our 492 previous studies suggested that decreased sex hormone concentrations in glaucoma lead to a 493 hyperinflammatory state, leading to faster rates of VF damage^{18,31}. Thus, we hypothesized that ⁴⁹⁴aromatase defects might lead to a decrease in estradiol levels and an increase in androstenedione,

495 causing an inflammatory response and leading to retinal ganglion cell death in patient with glaucoma ⁴⁹⁶(Figure S14B). In addition, androstenedione converted to estrogens is catalyzed by the aromatase ⁴⁹⁷(Figure S14C). Furthermore, some of the metabolites might also be linked to PACG physiological ⁴⁹⁸processes that remain unclear, and future research in this field is needed. Sex hormones, including ⁴⁹⁹androstenedione, might be associated with glaucoma types such as POAG, normal-tension glaucoma, 500 and pseudoexfoliation glaucoma³². The precise molecular mechanisms remain unclear. More 501 research is essential to understand their relationship with different glaucoma types.

⁵⁰²Furthermore, other studies have also found significant correlations between androstenedione and 503 other diseases. For example, Javier et al.³³ found that androstenedione can predict the progression of ⁵⁰⁴Frailty Syndrome in patients with localized breast cancer treated with aromatase inhibitors. 505 Adriaansen et al.³⁴ reported that diurnal salivary androstenedione levels in healthy volunteers for 506 monitoring treatment efficacy of patients with congenital adrenal hyperplasia.

⁵⁰⁷As far as our understanding goes, this is the initial investigation to methodically outline blood 508 metabolites and scrutinize the diagnostic efficacy of a potential biomarker for PACG. Nevertheless, 509 our study is not without its limitations: (1) The supplementary phase of our study was conducted 510 with a restricted number of patients and healthy controls. Therefore, further investigations with larger 511 sample sizes are necessary to confirm the diagnostic accuracy of serum androstenedione for the 512 detection of primary angle-closure glaucoma (PACG). (2) Our study cohort exhibited uniform ⁵¹³genetic and environmental traits, which may restrict the generalizability of our findings to 514 populations with diverse ethnic or racial backgrounds. (3) Despite the matching of PACG patients 515 and controls for age, gender, BMI, hypercholesterolemia, hypertension, diabetes, smoking, and 516 drinking, it is possible that unidentified residual confounding factors could impact the observed 517 metabolomic disparities. (4) Throughout the duration of the follow-up period, the majority of 518 individuals received pharmacological treatment, and the study's follow-up period was limited to a 519 mere two years. Consequently, the outcomes may have been impacted by either behavioral 520 adjustments prompted by patients' cognizance of their medical condition or by any form of 521 therapeutic intervention. (5) Despite our examination of the impact of hormone intake (including 522 estrogen, progestagen, and anti-androgen), the potential influence of reproductive aging cannot be 523 entirely dismissed. (6) Understanding the link between changes in androstendione levels and

524 glaucoma severity might hinge on metabolic and anti-inflammatory pathways. However, the current 525 study did not delve deeply into the mechanism verification. Further research is essential to 526 comprehensively grasp the precise relationship between androstendione and the severity of glaucoma, 527 as well as the mechanisms at play.

-
- ⁵²⁸**5. Conclusions**

⁵²⁹In conclusion, androstenedione has been identified and validated through the use of widely-targeted ⁵³⁰LC-MS or targeted chemiluminescence immunoassay, demonstrating its ability to effectively 531 differentiate between healthy individuals and those with PACG. Additionally, baseline 532 androstenedione levels may serve as a valuable predictor of glaucomatous VF progression. However, 533 further clinical and basic studies are required to confirm the clinical utility of serum androstenedione 534 for early-stage PACG diagnosis, as well as its potential for monitoring/predicting VF progression and 535 elucidating the underlying mechanisms linking androstenedione to PACG.

536 536

⁵³⁷**Declarations**

⁵³⁸**Ethics approval and consent to participate:** This study was approved by the Ethics Committee of ⁵³⁹Eye and ENT Hospital of Fudan University (EENT-2015011) and was conducted under the 540 Declaration of Helsinki. All participants provided written informed consent prior to their 541 participation.

⁵⁴²**Consent for publication:** Not applicable.

⁵⁴³**Availability of data and materials:** The datasets used and/or analyzed during the current study are 544 available from the corresponding author on reasonable request.

⁵⁴⁵**Competing interests:** No conflicting relationship exists for any author.

⁵⁴⁶**Funding:** This work was supported by Youth Medical Talents – Clinical Laboratory Practitioner 547 Program (2022-65), the National Natural Science Foundation of China (82302582), and Shanghai 548 Municipal Health Commission Project (20224Y0317). The sponsor or funding organization had no 549 role in the design or conduct of this research.

⁵⁵⁰**Authors' contributions:** Shengjie Li, Shunxiang Gao and Wenjun Cao contributed to the study 551 conception and design, data analysis, interpretation of the data, and drafting the manuscript. Yichao 552 Qiu, Jun Ren, Zhendong Jiang, Yingzhu Li, Yunxiao Song, and Mingxi Shao contributed to the

- 8. Sun, X. *et al.* Primary angle closure glaucoma: What we know and what we don't know. *Prog*
- *Retin Eye Res* **⁵⁷**, 26–45 (2017).
- 9. J, Y. *et al.* Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of
- 580 response to corticosteroids. *EBioMedicine* **84**, (2022).
- 581 10. Guijas, C., Montenegro-Burke, J. R., Warth, B., Spilker, M. E. & Siuzdak, G. Metabolomics
- 582 activity screening for identifying metabolites that modulate phenotype. *Nat Biotechnol* 36, 316– 583 320 (2018).
- 11. Hysi, P. G. *et al.* Ascorbic acid metabolites are involved in intraocular pressure control in the general population. *Redox Biol* **²⁰**, 349–353 (2019).
- 12. Wang, Y., Hou, X.-W., Liang, G. & Pan, C.-W. Metabolomics in Glaucoma: A Systematic Review. *Invest Ophthalmol Vis Sci* **⁶²**, 9 (2021).
- 13. Tang, Y. *et al.* Metabolomic Profiling of Aqueous Humor and Plasma in Primary Open Angle
- Glaucoma Patients Points Towards Novel Diagnostic and Therapeutic Strategy. *Front Pharmacol* **¹²**, 621146 (2021).
- 14. Rong, S. *et al.* Long-chain unsaturated fatty acids as possible important metabolites for primary
- angle-closure glaucoma based on targeted metabolomic analysis. *Biomed Chromatogr* **³¹**, (2017).
- 15. Kang, J. H. *et al.* Prediagnostic Plasma Metabolomics and the Risk of Exfoliation Glaucoma.
- *Invest Ophthalmol Vis Sci* **⁶³**, 15 (2022).
- 16. Li, S. *et al.* Serum complement component 3, complement component 4 and complement 596 component 1q levels predict progressive visual field loss in older women with primary angle closure glaucoma. *Br J Ophthalmol* bjophthalmol-2021-320541 (2022) 598 doi:10.1136/bjophthalmol-2021-320541.
	-

- 17. Li, S. *et al.* Association of systemic inflammation indices with visual field loss progression in
- 600 patients with primary angle-closure glaucoma: potential biomarkers for 3P medical approaches.
- *EPMA J* **¹²**, 659–675 (2021).
- 18. Li, S. *et al.* Association Between 17-β-Estradiol and Interleukin-8 and Visual Field Progression
- in Postmenopausal Women with Primary Angle Closure Glaucoma. *Am J Ophthalmol* **²¹⁷**, 55– 604 67 (2020).
- 19. Chen, Y. *et al.* Lack of Association of rs1192415 in TGFBR3-CDC7 With Visual Field
- Progression: A Cohort Study in Chinese Open Angle Glaucoma Patients. *Front Genet* **⁹**, 488 (2018).
- 20. Naghizadeh, F. & Holló, G. Detection of early glaucomatous progression with octopus cluster trend analysis. *J Glaucoma* **²³**, 269–275 (2014).
- 21. Gong, L. *et al.* All-In-One Biomimetic Nanoplatform Based on Hollow Polydopamine Nanoparticles for Synergistically Enhanced Radiotherapy of Colon Cancer. *Small* **¹⁸**, e2107656
- 612 (2022).
- 22. Obuchowski, N. A. & Zhou, X.-H. Prospective studies of diagnostic test accuracy when disease prevalence is low. *Biostatistics* **³**, 477–492 (2002).
- 615 23. Li, J. & Fine, J. On sample size for sensitivity and specificity in prospective diagnostic accuracy
- studies. *Stat Med* **²³**, 2537–2550 (2004).
- 24. Qin, Y. *et al.* Association between plasma free fatty acid levels and primary angle-closure
- glaucoma based on a mass spectrometry metabolomics analysis. *Acta Ophthalmol* **¹⁰⁰**, e204– 619 e212 (2022).
- 25. Prokai-Tatrai, K. *et al.* 17β-estradiol eye drops protect the retinal ganglion cell layer and

- preserve visual function in an in vivo model of glaucoma. *Mol Pharm* **¹⁰**, 3253–3261 (2013).
- 26. Madjedi, K. M. *et al.* The Association of Female Reproductive Factors with Glaucoma and
- Related Traits: A Systematic Review. *Ophthalmol Glaucoma* S2589-4196(22)00096–5 (2022)
- doi:10.1016/j.ogla.2022.06.003.
- 27. Feng, L. R., Barb, J. J., Allen, H., Regan, J. & Saligan, L. Steroid Hormone Biosynthesis
- 626 Metabolism Is Associated With Fatigue Related to Androgen Deprivation Therapy for Prostate
- Cancer. *Front Cell Dev Biol* **⁹**, 642307 (2021).
- 28. Schiffer, L. *et al.* Human steroid biosynthesis, metabolism and excretion are differentially
- 629 reflected by serum and urine steroid metabolomes: A comprehensive review. *J Steroid Biochem*
- *Mol Biol* **¹⁹⁴**, 105439 (2019).
- 29. Vajaranant, T. S. *et al.* Racial Differences in the Effects of Hormone Therapy on Incident Open-

Angle Glaucoma in a Randomized Trial. *Am J Ophthalmol* **¹⁹⁵**, 110–120 (2018).

- 30. Engler-Chiurazzi, E. B., Brown, C. M., Povroznik, J. M. & Simpkins, J. W. Estrogens as
- neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury. *Prog Neurobiol* **¹⁵⁷**, 188–211 (2017).
- 31. Qiu, Y. *et al.* Association Between Sex Hormones and Visual Field Progression in Women With
- Primary Open Angle Glaucoma: A Cross-Sectional and Prospective Cohort Study. *Front Aging*
- *Neurosci* **¹³**, 756186 (2021).
- 32. Bailey, J. N. C. *et al.* Testosterone Pathway Genetic Polymorphisms in Relation to Primary
- Open-Angle Glaucoma: An Analysis in Two Large Datasets. *Invest Ophthalmol Vis Sci* **⁵⁹**, 629–
- 641 636 (2018).
- 33. García-Sánchez, J., Mafla-España, M. A., Torregrosa, M. D. & Cauli, O. Androstenedione and

- 643 Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One
- 644 Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors.
- ⁶⁴⁵*Biomedicines* **¹⁰**, 1634 (2022).
- ⁶⁴⁶34. Adriaansen, B. P. H. *et al.* Diurnal salivary androstenedione and 17-hydroxyprogesterone levels
- 647 in healthy volunteers for monitoring treatment efficacy of patients with congenital adrenal
- ⁶⁴⁸hyperplasia. *Clin Endocrinol (Oxf)* **⁹⁷**, 36–42 (2022).

⁶⁵¹**Figure 1.** Study design and workflow. A 5-phase study (discovery phase [discovery set 1, the 652 discovery set 2], validation phase 1, validation phase 2, supplemental phase, and cohort phase) 653 design. A: The workflow of the discovery phase, validation phase 1, supplemental phase, and cohort 654 phase were analyzed by liquid chromatography-mass spectrometry (LC-MS) for untargeted 655 metabolomics. B: The workflow of validation phase 2 was analyzed chemiluminescence 656 immunoassay for targeted detection. C: A total of 440 patients and controls were recruited and 657 assigned to discovery set 1 (n = 140), the discovery set 2 (n = 180), and validation set 1 (n = 120). 658 The biomarker signature was identified on the metabolomic data from the discovery phase, 659 comparing primary angle closure glaucoma (PACG) with control patients. These data were used as a 660 discovery set for the algorithm. D: Validation phase 2 (n = 176) was included as the second 661 validation cohort. E: Three measurements were performed in the supplemental phase. F: Cohort 662 phase were performed to validate the predictive value of biomarker ($n = 97$).

a de de cla de de de de de de de

⁶⁶⁴**Figure 2.** Metabolic profiles discriminate participants with primary angle closure glaucoma (PACG) 665 from normal controls (NC). A: Orthogonal projection to latent structure-discriminant analysis ⁶⁶⁶(OPLS-DA) score plot of the comparison between the PACG and NC groups in the discovery phase ⁶⁶⁷(discovery set 1 and discovery set 2). Samples in the encircled areas are within the 95% confidence 668 interval. B: Volcano plot of differential metabolites. Metabolites with a fold change of $\langle 0.85 \rangle$ and a 669 false discovery rate (FDR) of ≤ 0.1 were considered significantly down-regulated. Metabolites with a 670 fold change of >1.15 and an FDR of < 0.1 were considered significantly up-regulated. Changes in 671 other metabolites were not significant (insignificant). C: Venn diagram displaying the 32 differential 672 metabolites that were altered as biomarker candidates from the two comparisons in the discovery 673 phase. D: Heatmap of differential metabolites in the discovery set 1 (Data were normalized to min-674 max). E: Heatmap of differential metabolites in the discovery set 2 (Data were normalized to min-675 max). FA: fatty acid.

A

676
677

Figure 3. Identification of a unique PACG-associated blood metabolite fingerprint and its behavior 678 in the discovery phase. A: Heatmap of the area under the receiver-operating-characteristic curve

- 679 assessing the discriminating accuracy of each of the 32 metabolites in differentiating PACG from
- 680 normal control in the discovery set 1 and discovery set 2. B: The eigenmetabolite of the 32-
- 681 metabolite cluster between primary angle closure glaucoma (PACG) and control patients in the
- 682 discovery set 1. C: The eigenmetabolite of the 32-metabolite cluster between primary angle closure
- 683 glaucoma (PACG) and control patients in the discovery set 2. Wilcox test was used.

⁶⁸⁵**Figure 4.** Biomarker discovery discriminates primary angle closure glaucoma (PACG) from normal 686 in the discovery phase. A: A heatmap of correlation analysis between ocular clinical characteristics 687 and 32 potential biomarkers in the discovery phase in PACG subjects. B: The serum level of 688 androstenedione between PACG(42852±20767) and normal(33987±11113) group in the discovery 689 set 1 (Unit for y-axis is peak areas). C: The serum level of androstenedione between PACG and 690 normal group in the discovery set 2 (Unit for y-axis is peak areas). D: Receiver operating 691 characteristic curves of androstenedione to discriminate PACG from normal in the discovery set 1. E: ⁶⁹²Receiver operating characteristic curves of androstenedione to discriminate PACG from normal in 693 the discovery set 2. Independent student's t-test was used.

⁶⁹⁵**Figure 5.** Biomarker validation in two independent validation phases to discriminate primary angle 696 closure glaucoma (PACG) from normal. A: The serum level of androstenedione between PACG and

697 normal group in validation phase 1 (Unit for y-axis is peak areas). B: The serum level of ⁶⁹⁸androstenedione between PACG and normal group in validation phase 2 (Unit for y-axis is peak 699 areas). C: Receiver operating characteristic curves of androstenedione to discriminate PACG from ⁷⁰⁰normal in validation phase 1. D: Receiver operating characteristic curves of androstenedione to 701 discriminate PACG from normal in validation phase 2. Independent student's t-test was used.

 \overline{a}

⁷⁰³**Figure 6.** Specificity of circulating androstenedione in patients with primary angle closure glaucoma ⁷⁰⁴(PACG) in supplemental phase. A: Sampling scheme and workflow to investigate the temporal 705 changes in androstenedione levels. B: Differential level of serum androstenedione between patients 706 with PACG before and three months after treatment (Unit for y-axis is peak areas). C: Sampling 707 scheme and workflow to determine whether aqueous humor levels of androstenedione were high in 708 patients with PACG. D: The aqueous humor level of androstenedione between PACG and cataract ⁷⁰⁹(Unit for y-axis is peak areas). E: Heatmap of correlation analysis between ocular clinical

710 characteristics and aqueous humor level of androstenedione. F: Comparison means aqueous humor 711 levels of androstenedione between mild, moderate, and severe PACG (Unit for y-axis is peak areas). ⁷¹²G: 7 paired serum-aqueous humor samples from the same PACG patients were included (Unit for y ⁷¹³and x-axis is peak areas). A significant correlation between serum and aqueous humor levels of 714 androstenedione was observed. Kruskal-Wallis test and one-way ANOVA was used. *P<0.05; **: 715 P<0.001.

716

- ⁷¹⁷**Figure 7.** Kaplan-Meier curves stratified by the men value in terms of androstenedione. A:
- 718 male+female; B: Female; C: Male. We categorized study participants into 2 groups based on their
- 719 mean levels of androstenedione.

720

721 Table 1. The clinical and demographic characteristics of all subjects in the discovery and validation phases

723 BMI =body mass index; $IOP =$ intraocular pressure, $VCDR =$ vertical cup-to-disc ratio, $AL =$ axial length, $CCT =$ central corneal thickness, $ACD =$ anterior chamber depth, MD: visual field mean

724 length, CCT = central corneal thickness, ACD = anterior chamber depth, MD: visual field mean deviation, MS: visual field mean sensitivity, $PACG = \text{primary angle closure}$ glaucoma.

deviation, MS: visual field mean sensitivity, PACG=primary angle closure glaucoma.

726

 729 IOP = intraocular pressure, VCDR = vertical cup-to-disc ratio, $AL = axial$ length, CCT = central corneal thickness, $ACD =$ anterior chamber depth, $MD =$ mean deviation, PACG=primary angle 730 corneal thickness, ACD = anterior chamber depth, MD = mean deviation, PACG=primary angle closure glaucoma.

731 closure glaucoma.
732 *adjusted for BM 732 *adjusted for BMI, diabetes (yes=1, no=0), hypertension (yes=1, no=0), hypercholesterolemia
 733 (yes=1, no=0), smoking (yes=1, no=0), and drinking (yes=1, no=0).

733 (yes=1, no=0), smoking (yes=1, no=0), and drinking (yes=1, no=0).
734